Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Altimmune (0A4C) Share Price & Analysis

0 Followers

0A4C Stock Chart & Stats

$2.89$0.00(0.00%)
At close: 4:30 PM GMT
$5$10$15$20Dec 1Nov 29Dec 2Dec 1
Day’s Range
$2.89 - $2.89
52-Week Range
$2.89 - $5.87
Previous Close
$2.89
Volume
N/A
Average Volume (3M)
0
Market Cap
$375.42M
Enterprise Value
$273.45M
Total Cash (Recent Filing)
$326.32M
Total Debt (Recent Filing)
$35.75M
Price to Earnings (P/E)
―
Beta
1.04
Next Earnings
Mar 03, 2027 (Est.)
EPS Estimate
-0.16
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical Pipeline Progress

Positive mid-stage data across several liver-disease measures supports pemvidutide’s clinical differentiation and gives Altimmune a credible basis for advancing development. If replicated in later trials, the breadth of observed effects could support a durable liver-focused franchise rather than a single-indication opportunity.

Cash Runway

The reported cash position provides visibility to continue the principal MASH program through a major clinical readout without an immediately required financing event. That runway supports consistent trial execution, preserves strategic flexibility, and gives management time to pursue partnerships or other funding options.

Broad Development Opportunity

Advancing one candidate across multiple serious liver and alcohol-related diseases can increase the value of the development platform and diversify potential future indications. Progress in several programs also creates multiple clinical milestones and may improve the company’s strategic positioning with partners.

Bears Say

Pre-commercial Financial Profile

Altimmune has not yet demonstrated recurring product revenue, while its research-led cost base produces substantial losses. This leaves future financial performance dependent on clinical success, financing, collaborations, or commercialization, making the path to self-sustaining operations uncertain over the next several quarters.

Sustained Cash Burn

Persistent cash outflows show that clinical and operating investment is consuming capital faster than the business generates it. Even with a substantial cash balance, continued burn can reduce flexibility over time and increase the eventual importance of partnerships, debt, or equity financing.

Long And Uncertain Development Path

Key value-defining catalysts remain years away, while the AUD registrational program still lacks firm timing and a funding plan. Regulatory feedback, final trial design, and financing requirements could alter execution speed and capital needs, extending uncertainty before any commercial revenue can emerge.

Altimmune News

0A4C FAQ

What was Altimmune’s price range in the past 12 months?
Altimmune lowest share price was $2.89 and its highest was $5.87 in the past 12 months.
What is Altimmune’s market cap?
Altimmune’s market cap is $375.42M.
When is Altimmune’s upcoming earnings report date?
Altimmune’s next earnings report is estimated for Mar 03, 2027 (not yet confirmed), which is in 110 days.
How were Altimmune’s earnings last quarter?
Altimmune released its earnings results on Nov 12, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.132 by -$0.018.
Is Altimmune overvalued?
According to Wall Street analysts Altimmune’s price is currently Undervalued.
Does Altimmune pay dividends?
Altimmune does not currently pay dividends.
What is Altimmune’s EPS estimate?
Altimmune’s EPS estimate is -0.16.
How many shares outstanding does Altimmune have?
Altimmune has 194,517,700 shares outstanding.
What happened to Altimmune’s price movement after its last earnings report?
Altimmune reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.132. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Altimmune?
Hedge funds hold Altimmune shares: the largest hedge-fund position in Altimmune is 884,919,017 shares, and hedge funds increased their holdings by 16.6M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology